Discussion of Phage Therapy for CF Patients - Rebekah Dedrick
The conversation
Episode notes
Bekah Dedrick joins Joe Campbell to explain what her work on compassionate use mycobacteriophage therapy taught her about treating infections in people with cystic fibrosis. Drawing on her laboratory experience and role at the Cystic Fibrosis Foundation, she explains why matching a phage to a patient’s bacteria is only the beginning.
Dedrick describes how thick mucus, biofilms and scattered infection sites complicate phage delivery in CF lungs, leaving the relative benefits of intravenous and nebulized treatment unresolved.
The POSTSTAMP protocol aims to make compassionate use cases more interpretable through shared endpoints and a comparator group of participants whose bacteria lack a phage match.
Testing one bacterial colony can miss the varied Pseudomonas population within a patient, and Dedrick argues that screening conditions also need to reflect the environment being treated.
Episode timeline
- 0:00 Introduction and Dedrick’s path to compassionate use phage therapy
- 9:31 Why CF lungs challenge treatment and what the Foundation supports
- 18:05 What compassionate use teaches about delivery and immune responses
- 22:12 Biology, manufacturing and clinical evidence gaps
- 27:33 Helping clinicians find phage screening laboratories
- 32:11 Making laboratory assays more predictive of treatment
Transcript
AI-transcribed and edited for readability. May contain errors or omissions; check the recording for exact wording.
Select a word or timestamp to listen. Use arrow keys to move between words.
- Joe Campbell
All right, it's a great pleasure today to have Bekah Dedrick from the Cystic Fibrosis Foundation to talk us a little bit about the Cystic Fibrosis Foundation and how they view phages as part of the treatment for cystic fibrosis patients. But to start out with, let's have—well, it's a great pleasure to have Rebekah here, and we'll have Rebekah tell us a little bit about what she did.
Before she came to the CF Foundation, mostly related to phages, but take it away, Rebekah.
- Bekah Dedrick
Thanks, Joe, and thanks for having me. It's a full circle moment to be on Podovirus. So, yeah, my path to the foundation actually, as I look back, was sort of serendipitous. Before I joined, I spent most of my scientific career looking—working with bacteriophages, mycobacteriophages specifically, and I was fortunate enough to end up in a space where that lab science sort of intertwined with clinical application. And it didn't happen immediately, but as I was a postdoc with Graham Hatfull at the University of Pittsburgh, then transitioned into a research associate position.
I saw that transition with my eyes. And of course, in Graham's lab, I worked for many years just characterizing mycobacteriophages. And so we were thinking about lytic phage, engineering temperate phage into lytic phage. I did a lot of gene expression studies looking at transcripts during phage infection, and looking at host range and just underlying phage genetics. So it was basic biology work at first, and then it took a turn towards the clinic.
When Graham was contacted by a clinician at the Great Ormond Street Hospital in London who had a patient with cystic fibrosis who had had a double lung transplant and was suffering from a Mycobacterium abscessus infection, and this clinician called Graham and said, hey, you have this huge collection of mycobacteriophages. Do you think any of them
would be able to infect my patient's isolate of Mycobacterium abscessus and potentially be able to treat her. And, you know, I'll never forget the moment where, you know, Graham came up to my bench and Carlos Guerrero and I were talking, and he presented this to us and we were like, yeah, you know, like send it, they should send it. We'll try it, you know, we'll try the phages on this isolate, look for susceptibility.
And that's what we ended up doing. This patient was on palliative care at the time. I didn't know what cystic fibrosis was. But we ended up treating this patient with a three-phage cocktail. And this was sort of the beginning of compassionate use mycobacteriophage therapy. And fortunately for Carlos and I, we were able to go to Great Ormond Street Hospital in London and meet this patient and meet the patient's family.
And be there for the administration of the mycobacteriophages for the very 1st time. And, you know, it was nerve-wracking. I mean, we were giving this patient IV phage. That had never been done before. Phage that were prepared in Graham's lab by like Debbie Jacobs-Sera. And of course, we followed as much regulatory sterility sort of guidelines as we could, but we weren't a GMP manufacturing facility.
And so, you know, we really didn't know what the phage would do inside a human body. You know, all of our experiments were, you know, in the lab in a dish. And so, you know, there I was at Great Ormond Street Hospital, face to face with that family that really represented it the last resort option for their child with this horrible infection. And that's where I learned…
About CF. And that involved not only the patient, but the patient's family and who was caring for the patient. So I was able to monitor the patient in real time while I was there, along with the clinical micro lab at the hospital. And that was where I was really able to see, you know, the—what everybody calls bench-to-bedside sort of therapy. And, you know, I actually was so struck by cystic fibrosis, the disease in general, at that point.
That I got involved with my local CF chapter. And I call myself a runner. I'm kind of a slow runner, but we have our local chapter does these Run for a Reason, and you can participate in different races, running races, and you can raise money for the foundation. And so I started getting involved with my local chapter and the whole lab was participating in either fundraising or running for a reason.
So that was kind of fun. A lot of our isolates came from patients with CF.
And
- Joe Campbell
In this case, you mean mycobacterial isolate, not phage isolates.
- Bekah Dedrick
That's right. That's right. So NTM, so mostly M. abscessus, but some…
You know, odd species like M. kansasii and M. chelonae and M. xenopi, but mostly M. abscessus and MAC. Of course, this patient's case was published in Nature Medicine. And, you know, she got, she got better, you know, she had this node in her liver that improved. She had sternal wounds from the lung transplant that improved. And once this case was published, it really opened up the door to people from all over the world.
Both patients and clinicians that, you know, contacted us and said, could you screen my patient's isolate or my isolate, my NTM isolate, and look for phage susceptibility? So it was really a pivotal time, I think, in the Hatfull lab and for me personally. After that case, then we publish a case study—case series of 20 patients that we treated with NTM infections with phage. And some of them had good outcomes, good clinical and microbiological outcomes, and some didn't.
And after that case series was published, then I moved to Janssen as a principal scientist, where basically I helped to design a clinical trial using phage therapy. Unfortunately, that program actually, before it even got off the ground, was de-prioritized, as we often see in the infectious disease area in large pharma settings. So when the opportunity came to move to the CF Foundation, you know, it felt like a natural next step.
And what I loved about the compassionate use work was that it was translational, but it really made clear, know, how many questions I couldn't answer from an N of one. And so I realized the need for trials, and I realize the foundation could sort of help stimulate that sort of research and that direction for phage therapy.
- Joe Campbell
So just a couple of quick follow-ups: in the 20-patient paper that you mentioned, were those all CF patients or were some of them not CF patients?
- Bekah Dedrick
Some of them were not. We did have some patients that were bronchiectasis. But I think most of them were lung infections, aside from maybe one or two that were skin. But yes, mostly lung infections, which I think is a difficult, difficult environment to treat, right, with phage and with drugs as well, just because of how the bacteria grow.
- Joe Campbell
Yeah. And I guess—well, because everything—there haven't been that many clinical trials, but is it your sense that the environment of the CF lung is different enough that the things you have to think about are a little bit different?
- Bekah Dedrick
Yeah, I mean, so, you know, I know, I know your audience is pretty phage knowledgeable, but let me just give a quick little background on CF. So CF is basically caused by a mutation in the CFTR gene. And this is basically a chloride bicarbonate channel that changes the airway surface in the lung. And so essentially when CFTR doesn't function, you get airway mucus that becomes dehydrated, it becomes hyper-viscous and it's really hard to clear.
And so this sets up a perfect environment for opportunistic pathogens to form infections. And so our number one bacteria that we see in patients with CF is Pseudomonas aeruginosa. But we also see Staph, Stenotrophomonas, NTM, Burkholderia, Achromobacter. And so we see some more than others, of course, you know, the most prevalent is Pseudomonas. But really that environment in the lung, because of the mucus and the inability to clear…
Really sets up a great environment to establish a chronic infection. And so you're really seeing biofilms develop. And because of the damage and architecture of the lung, you know, oftentimes it's—the infections kind of sit in different places, so it's not just like one group, you know, in one place. So these are the sort of things that researchers need to think about when they think about the CF lung.
And getting the therapy where it needs to go, of course. There's this debate about, should we use nebulized phage therapy? Should we use IV phage therapy? And I don't know the answer to that question. But you could imagine positives and negatives for both methods of delivery, but I think that's something that still needs to be researched rigorously and figured out for patients with CF specifically.
- Joe Campbell
Yeah. And I guess the next question sort of is where—how do you think phages are going to—what role do you think phages are going to play in the future in the treatment of CF patients? Is it going to be mostly compassionate use cases, or…
- Bekah Dedrick
Yeah, I mean, I think the Foundation's role is really to help answer the questions that need to be answered before phage therapy can reach people with CF broadly and reliably. And that really means investing across the whole translational continuum, right? At the basic end, we're supporting research on phage biology that informs therapy, so how phages interact with the human immune system, especially with repeat dosing, which obviously is necessary.
How they penetrate the CF sputum, as we talked about, in the biofilms that develop. How they behave in that specific airway environment, and how phage resistance evolves in the CF lung. At the translational clinical end, we support studies that evaluate specific phage approaches both in industry-sponsored programs as well as academic-led compassionate use protocols. One I'll mention, because it's a nice example of a standardized sort of protocol, is the POSTSTAMP study.
And so this is led by Jerry Nick and Graham Hatfull out of National Jewish Health. And essentially it's a multi-site CF Foundation-sponsored ancillary protocol through our NTM consortium that basically evaluates mycobacteriophage therapy
for treatment of refractory M. abscessus in people with CF, and this uses FDA IND-based compassionate use protocols with specific microbiological and clinical endpoints. There's a standardized protocol, as I mentioned. There's also a comparator arm, which is pretty cool. It's made up of participants who essentially don't have a phage match. And the idea there is to sort of convert what has been an extremely heterogeneous, as you know, N of one sort of studies…
into interpretable data with a group. And although it is still heterogeneous, you do have a comparator arm. And it's really meant to give the field a template for these sort of compassionate use cases. I think that one thing that the foundation has that I don't think many people know about is our—we have this diverse infrastructure, I think, that can help researchers both academically and then also in the industry. We have a therapeutic development network.
Which is basically a clinical trial network with sites and expertise to execute basically complex CF studies. We also have a patient registry essentially that captures all of the patients with CF in the US. That gives us visibility into pathogen prevalence, resistance patterns, outcomes of patients after specific therapies. And we have a clinical trial navigator that allows patients and clinicians to sort of find appropriate clinical trials and pathways in order to best suit them.
So I think, you know, to close this out, I mean, I think the foundation is not necessarily going in with a goal of proving that phage can work. Some of us already believe that, right? And the goal is to understand when they work, why they work and how we can turn these therapies into safe, reliable and accessible therapies for people with CF.
- Joe Campbell
Yeah, no, I think that's very important. And just to be clear, you were talking about some of the things that the CF Foundation does. When you say it does that, are there people who are directly employees of the CF Foundation, or are you funding people like Jerry Nick or something to do the things that you were talking about doing, but they are at other institutions?
- Bekah Dedrick
Yeah. So the TDN is directly funded, but they are at other institutions. So like Jerry Nick at National Jewish Health, and we do fund that. The patient registry is part of the foundation, and yes, we completely cover that. So yeah, I mean, the infrastructure that the foundation provides is amazing, and I think it's really useful when we have industry partners that want to do clinical trials in people with CF, I think.
It's beneficial to us because we can say, hey, look, we have these resources, you know, and we can help you move to the next step.
- Joe Campbell
Right. So, you know, I think the next question I was supposed to ask you is, how does—how do you see the CF Foundation maximizing the potential of phage therapy for CF patients? But I think you basically…
- Bekah Dedrick
That's pretty much—I…
Yeah.
- Joe Campbell
And, you know, and obviously it's the—all the—all the resources that you just outlined, so that I think we'll move to—so, what are your thoughts? And again, you've touched on some of this, but do you have specific thoughts about the role of clinical trials versus compassionate use?
- Bekah Dedrick
Yeah. I mean, I think both are super important. I think that, you know, of course, compassionate use—you know, basically expanded access, right, under emergency authorization—is how we give a person that has no other options a shot at phage therapy, right? I've personally participated in a lot of these cases. I understand—well, maybe I don't understand fully, but I've seen the devastating news that we don't have any more antibiotics that could work for your specific infection and there's nothing else we can do.
And so some of these patients, you know, obviously are desperate. I mean, some of them are parents of kids that have these terrible infections, and they're just drug resistant. So I definitely see a place for compassionate use therapy. And it obviously matters enormously to the individuals involved. And these cases have really taught the field, you know, a huge amount about what phage therapy looks like in practice, right?
We've seen IV delivery, we've seen nebulized delivery, we've seen delivery combining phages with antibiotics.
The field has dug into neutralizing antibody responses, which, you know, of course, I'm into that.
- Joe Campbell
Yeah, Well, you're one of the first people that was involved in identifying them back in one of your many previous lives.
- Bekah Dedrick
Yes. Yes. And, you know, that's—it's important to understand, you know, neutralizing antibodies when you're thinking about a chronic infection that you're going to have to treat for longer than a couple of days or even a couple of weeks, especially with NTM. I mean, we obviously, we treated patients for many months. So neutralizing antibodies is a concern. And not only that, but just the human immune response, no matter if it's neutralizing or not.
What role does that play?
- Joe Campbell
And do you—I mean, I know it's early days, but do we have any sense of—you mentioned IV versus nebulized, and I'm sure there's other routes of administration. Is there any, like, glint of any hint of, like, one of them might be less prone to…
- Bekah Dedrick
I don't know. I mean, I've heard people say, well, if you give it by IV, you're basically giving the phage to the sharks, right? Because there's sharks in the blood that will then neutralize the phage or destroy the phage, and that if you nebulized, you know, maybe the phages have more of a chance to get where they need to be and multiply, right? But I think the CF lung…
You know, there is a lot of—there are a lot of immune cells there, and so we have to kind of think through that with each sort of disease that we're treating, or infection, I guess, that we're treating. So I think it's going to differ for each infection. I don't know what is best, you know, and this is still something that I think we're trying to figure out.
I think most of the CF trials that have happened so far with phages have been nebulized.
So we'll see.
- Joe Campbell
So I think you've touched on some of them, but the last thing I wanted you to talk about was, what do you see as the biggest roadblocks?
- Bekah Dedrick
Yeah.
- Joe Campbell
Reaching its full potential for CF patients.
- Bekah Dedrick
I think as far as roadblocks go, you know, getting to your question, I think first it's essentially the biology. There's several buckets, but first, the biology, right? So we still don't understand, as I alluded to, some of the phage-host interactions, especially with people with CF. Immunogenicity, of course, as we talked about, I think that's a big one. How—with repeat administration, with delivery, with doses, I mean.
Doses are still—I mean, I think we're sort of, you know, hopefully we're aligning somewhere, but I think it's still kind of a mixed bag on dosing. And so, you know, PK, I think, you know, pharmacokinetics and tissue distribution in the CF airways is something that needs to be researched a little bit better. You know, when you're giving a phage that's self-replicating into this mucus-laden, biofilm-rich environment with local immune activity…
We just don't have the right predictive models. And when you're doing—you know, I know for one, you know, I've done, it is like compassionate use therapy. You're just looking on a plate, and you're growing up the patient's isolate, and you're looking for phage susceptibility. It really—for compassionate use therapy, you know, you're under a time crunch, and that's suitable. But thinking about what we need to learn and how we need to screen…
For large clinical trials to move forward, I think, is important, because it may not just be, let's look and see if phage infect in a dish, right? In order to sort of bridge that in vitro success to in vivo success. And I think, you know, another thing is, you know, manufacturing. Although, you know, we now have facilities that, you know, do GMP manufacturing of phage, I think that, you know, thinking about consistent GMP-grade production…
You know, with endotoxin characterization, stable formulations for delivery, you know. These are all, you know, things that I think are still—you know, we've made a lot of progress, but I think there's still, you know, questions to be answered and just levels of rigor that we can sort of nail down a little bit better. And then, you know, as far as, like, clinical evidence, we still need, like, well-designed clinical trials.
With meaningful endpoints. And we need that to build our evidence base for people with CF. I don't think it's a secret that the field has just come across—the CF field has come across a setback in a phage therapy trial that was discontinued after unexpectedly high adverse events. It's hard, but I'd argue that it's one of the most important things that could have happened right now in CF because it's sort of forcing us to, you know, look at, you know.
Phage selection, dosing, you know, regulation, you know, immune response, all these things, you know, it's forcing us to dig deeper and really try to sort some of this stuff out. And of course this is the first time that we've seen any sort of safety signal with phage. And so it's great to get to the bottom of this. And the CF Foundation is, you know, is going to do that.
We're looking into—we have obtained the samples associated with the trial. And we have research ongoing that hopefully will bring some answers to the field.
- Joe Campbell
Yeah, You were telling me a little bit about that and it sounds like you guys are, as usual, doing the right thing. So hopefully—we're trying—the
A couple roadblocks that I was thinking you might mention that you didn't: is it your impression that the collections of phages that are available—so sort of walking through the experience of a doctor has a CF patient who's not responding to antibiotics anymore because of resistance to the antibiotics—and they come looking, are they—how hard is the process of finding a lab that has a phage that can help them?
And, you know.
Is—do we have enough phages and are they the phages that we have easy enough for clinicians to find?
- Bekah Dedrick
Yeah, I mean, it's a—it's a—it's an interesting question and I think one that a lot of groups are trying to understand and develop. And what you're speaking about is essentially what I think in my head as, like, a roadmap. Can a clinician say, okay, I have this patient, I don't have anything else for them. How can I contact? Where do I start? Where do I start?
And is there, like, a roadmap that we can put together that says, okay, now if your patient has an NTM infection that you can't treat, you know, you should send the isolate to this place and they will screen it for phage susceptibility. Bottom line is there's a lot of labs that are trying to do compassionate use therapy. And so, you know, it would be great. I think this comes to a different sort of
You know, box, but it would be great if we could get more standardization, right? And I think people are leaning towards that. How can we standardize? If different labs are screening, how can we make sure that, you know, this cocktail is—it was made or it was screened against this patient's isolate the same as it was, you know, if you did it somewhere else in Spain or something?
So I think that sort of rigor is currently being developed and I think that's good, but I think what you're speaking of is sort of like a roadmap. And I agree. I think that needs to be mapped out.
And bottom line is I think clinicians find labs that take these isolates through word of mouth. I think that's how it's passed right now, you know. And unfortunately, I do think that there are clinicians that just don't know. I still think that that's where we are in the field. There's people that know and there's people that just do not know and we have a responsibility to sort of get that, get that out there and have that be an option for these patients, especially with patients with CF.
I mean, oftentimes, as I said, they have these very different infections like Burkholderia, Stenotrophomonas, Achromobacter. And there's not a whole lot of labs that are looking at developing phage for these organisms. So, you know, there might be one lab that does it. And so, like I say, like pointing them in the right direction, right.
- Joe Campbell
And I guess, so if, for example, a CF doctor who doesn't know what to do and might have a patient is listening to this podcast, should they contact you? Should they—I mean, what's sort of a general advice? Obviously it depends on What?
- Bekah Dedrick
Yeah,
- Joe Campbell
what the isolate is that the person is infected with, but what's their best plan?
- Bekah Dedrick
Yeah. So typically CF care centers will have access to, you know, people at the foundation such as myself or, you know, clinicians that have dealt with this in the past. By all means they can reach out to me. But I think that our care centers are well aware of compassionate use phage therapy and also phage clinical trials. So I would say, you know, they could talk to people at their care center.
They could essentially email me. That's totally fine. And other non-CF clinicians, I think most of them find out just through other people that have done it, other clinicians that have administered phage or read about it in a paper and thought, oh, okay, I'm going to contact the author and see if they can take this isolate. And that's essentially what happened at the Hatfull lab, right?
People saw our Nature Medicine paper and thought, oh, I'm going to contact these people and see if they can screen the isolate. So I think that that really is the way to go, but yeah, for people with CF, the foundation provides this great network. And I think that that's a great way for us to make sure our patients have access.
- Joe Campbell
Yeah.
I'm going to ask you one more question about in vitro assays and, you know, for me, I'll just say personally, my view is that there's at least two big issues. The one that you sort of alluded to, which is, you know, a lab in Pittsburgh and a lab in California getting the same answer with the same. And that's a very complicated issue because, you know, are they going to use the same phage prep?
Are they going to have, you know, it's more complicated than what, like with antibiotics where everyone is in theory, order the antibiotic from Sigma and hopefully get the same thing. So that there's that complication. But I think there's also the issue of, you know, because as we talked about, or you talked about, there's so many things we don't know. And one of the things I think we don't know is whether
An assay in liquid is better or worse than a plate assay at predicting whether the phage is going to be efficacious clinically. That's something we really don't know. I mean, this was true. I don't know if, you know, I remember when I was at NIAID when people were worrying about Ebola assays. The reproducible assays were with transformed cell lines that had been, you know, used over and over again and you could kind of
- Bekah Dedrick
They behave
- Joe Campbell
There Was a lot of evidence that people started realizing that those were probably less clinically relevant than fresh cells which were less reproducible. So I mean, I guess what I'm asking is, you know, I guess as we're developing clinical trials, it's also going to be useful to understand what the in vitro assays were and decide which ones might be more predictive. And I guess that's a real future thing.
And I don't know if you want to comment on anything. Or just tell me to stop babbling.
- Bekah Dedrick
No, I like that question because, you know, something that sort I alluded to and maybe I didn't make super clear is related to this in vitro testing. So one of the things that we have learned about people with CF is when they have, for example, a Pseudomonas infection and, as I said, oftentimes they're chronic and they've had them for decades. What happens is that it's not this, you know.
One single strain in a patient. This, it's a population that becomes heterogeneous. And so, you know, and I often think about this like the clinical micro lab. They're taking a sputum sample and they're plating it and they're picking a colony and they're sending that out, right, for testing for MIC or phage susceptibility. And that really doesn't represent the heterogeneous population of Pseudomonas that's in that particular patient.
And so I think that's something that we need to think about.
And then as far as the assays go, you're right, I mean, do you do assays on agar and do you use LB or do you use something that—a media that's more specific, that mimics the CF lung environment?
You know, so I think all of these things matter. Do you use liquid? Liquid killing assays, and then what's the liquid that you use? Do you use L B for that? Do you use something more specific to the CF lung? And is that different for wound infections? So you often see Pseudomonas and wound infections. Can you use the same media that you're using to screen for CF
For wound infections? I mean, maybe not, right? Just because they're so different. And you could imagine. So why are they different? Well, because they're growing different. There's different receptors that are available on the surface, so maybe phage that can infect from bacteria in CF lung environment, whatever receptors were expressed and displayed there are completely different than phage receptor or bacterial receptors that are exposed for the phage to recognize in a wound infection.
Right. And so you have to think about all of this. And maybe, you know, I know that the field has really embraced, you know, engineering technologies and so, you know, you can, you know, we've seen publications, right, that people are manipulating tail fibers and maybe you're able to design a cocktail that, yep, it's going to work for CF lung infections and yep, it's going to work for wounds.
I mean, who knows, who knows what the future holds? But I mean, I think the whole engineering sort of pathway for phages is interesting and I think it could be a ticket to being able to kill maybe more efficiently depending on what's going on, you know, in the lung or in that specific infection. And so I think that will be an interesting subject to sort of follow as phage therapy progresses.
- Joe Campbell
Great. Well, I'm going to thank you so much and give you a chance to say anything that you didn't say. But we covered a lot of ground, so maybe you covered everything.
- Bekah Dedrick
Yeah, I mean,
- Joe Campbell
thank you so much for. Your thoughts and
- Bekah Dedrick
Yeah, absolutely. I just want to emphasize that the foundation is still really interested in phage therapy for people with CF. We fund a lot of different antimicrobial therapies. But phage is definitely—we think will be another tool in our toolbox. So we're excited about it and thanks for giving me this opportunity, Joe.
- Joe Campbell
You're welcome. Always great to talk to you in informal and slightly more formal setting.
- Bekah Dedrick
That's right.
